AI Article Synopsis

  • The study analyzed the levels of polycyclic aromatic hydrocarbons (PAHs) in infant and follow-up formulae sold in Nigeria to assess potential health risks to children.
  • The concentrations of PAHs were quite low, with benzo(a)pyrene (BaP) being below the European limit for infants, indicating minimal risk.
  • The estimated daily intake and margins of exposure for PAHs in these formulae suggest that they are comparable to European standards, showing no significant health risks for infants consuming these products.

Article Abstract

The concentrations and profiles of polycyclic aromatic hydrocarbons (PAHs) in commercially available infant formulae and follow-up formulae in Nigeria were determined with a view to providing information on the health risks to children from the consumption of these infant foods. The concentrations of PAHs were measured by means of gas chromatography-mass spectrometry (GC-MS) after extraction by ultrasonication with acetone/dichloromethane and clean-up. The concentrations of the Σ16 PAHs in these infant formulae ranged from 0.102 to 1.98 μg kg(-1), 0.054-1.98 μg kg(-1), 0.081-2.54 μg kg(-1) and 0.51-0.70 μg kg(-1) for infants of ages 0-6 months, 6-12 months, 1-3 years and 0-12 months respectively. The concentrations of benzo(a)pyrene (BaP) in all samples investigated were below the 1 μg kg(-1) European Commission permissible limit for BaP in foods meant for infants. The estimated daily intake of PAHs based on the European Food Safety Authority (EFSA) suggested indicators of occurrence and effects of PAHs in foods were not detected (nd) to 2.67 ng BaP kg(-1) bw day(-1), nd-5.29 ng PAH2 kg(-1) bw day(-1), nd-11.20 ngPAH4 kg(-1) bw day(-1) and nd-34.96 ng PAH8 kg(-1) bw day(-1). The estimated margin of exposure (MOE) values: BaP-MOE, PAH2-MOE, PAH4-MOE and PAH8-MOE values were greater than 10,000 which indicates that there are no health risks from the consumption of these products by infants. The concentrations and dietary exposure to PAHs from these products were similar to values reported in the literature for European Communities.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2014.06.026DOI Listing

Publication Analysis

Top Keywords

μg kg-1
20
kg-1 day-1
16
infant formulae
12
kg-1
9
polycyclic aromatic
8
commercially infant
8
formulae nigeria
8
health risks
8
concentrations
6
pahs
6

Similar Publications

Background: Subarachnoid hemorrhage (SAH) is a severe and emergent cerebrovascular disease, the prognosis of which usually very poor. Microthrombi formation highlighted with inflammation occurs early after SAH. As the main cause of DCI, microthrombosis associated with the prognosis of SAH.

View Article and Find Full Text PDF

Triolimus is a multi-drug loaded polymeric micelle containing paclitaxel (PTX), 17-allylamino-17-demethoxygeldanamycin (17-AAG), and rapamycin (RAP). This study examines the radiosensitizing effect of Triolimus in vitro and in vivo. Radiosensitizing effects of Triolimus on A549 cells are dose dependent and at 2 × 10 m, Triolimus shows significant radiosensitization even at low radiation doses (2 Gy).

View Article and Find Full Text PDF

1. The plasma clearance of the first-in-class DOT1L inhibitor, EPZ-5676 (pinometostat), was shown to be markedly lower in human compared to the preclinical species, mouse, rat and dog. 2.

View Article and Find Full Text PDF

Aims: The primary aim of this study was to describe the pharmacokinetics of total and unbound bupivacaine and ropivacaine following epidural bolus and infusion in neonates and young infants. Secondary aims were to investigate the influence of alpha-1-acid glycoprotein (AAG) on the concentration-time profiles and to determine the efficacy and adverse event profile of the epidural regimen.

Methods/materials: Thirty-one infants aged 40-63 weeks of postmenstrual age (PMA) undergoing hernia repair or abdominal surgery received an epidural injection of 1.

View Article and Find Full Text PDF

Background: The aims of this study were to evaluate pharmacokinetics, efficacy and safety of ropivacaine in infants aged 0-12 months following a single caudal injection.

Methods: Term ASA I-III patients, scheduled for surgery, with a body weight of > or = 2500 g received a caudal block with ropivacaine 2 mg x ml(-1), 1.0 ml x kg(-1).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!